Tyra Biosciences, Inc. (TYRA)

17.85 -0.68 (-3.67%) At close: 04:00PM EDT

Tyra Biosciences, Inc.

2656 State Street
Carlsbad, CA 92008
United States
619 728 4760
https://tyra.bio

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 49

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Todd Harris Ph.D.	Co-Founder, President, CEO, Secretary, Treasurer & Director	1.07M	N/A	1979
Mr. Alan Fuhrman	Chief Financial Officer	763.09k	N/A	1957
Dr. Hiroomi Tada M.D., Ph.D.	Chief Medical Officer	816.31k	N/A	1964
Mr. Daniel Bensen	Co-Founder & COO	630.8k	N/A	1976
Dr. Robert L. Hudkins Ph.D.	Chief Technology Officer	N/A	N/A	1956
Dr. Ronald V. Swanson Ph.D.	Chief Scientific Officer	536.19k	N/A	1964
Mr. Ali D. Fawaz J.D.	General Counsel	629.23k	N/A	N/A
Ms. Sarah Honig	Vice President of Corporate Development & Strategy	N/A	N/A	N/A
Dr. Piyush R. Patel Ph.D.	Chief Development Officer	N/A	N/A	1966
Amy Conrad	Investor Contact	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Corporate Governance

Tyra Biosciences, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 7. The pillar scores are Audit: 4; Board: 6; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.